natgillin/translations-raw huggingface dataset:
The use of Inbrija is not recommended in patients under 18 years of age.
Djeca i adolescenti Primjena Inbrije ne preporučuje se u bolesnika mlađih od 18 godina.
If you forget to use Inbrija
Ako ste zaboravili primijeniti Inbriju
Before starting Inbrija, you must be taking regular treatment for Parkinson's disease combining a socalled dopa-decarboxylase inhibitor with levodopa.
Prije nego što počnete primjenjivati Inbriju već morate uzimati redovitu terapiju za Parkinsonovu bolest koja kombinira takozvani inhibitor dopa-dekarboksilaze s levodopom.
A dose adjustment of levodopa may be required with concomitant use of COMT inhibitors.
Može biti potrebno prilagoditi dozu levodope kada se istodobno primjenjuju inhibitori KOMT-a.
Serious adverse reactions of allergic oedema have been reported with levodopa medicinal products but not in clinical studies with Inbrija.
Ozbiljne nuspojave alergijskog edema zabilježene su kod primjene lijekova koji sadrže levodopu, ali ne u kliničkim ispitivanjima s Inbrijom.
Flatulence,
flatulencija,
Patients with a major psychotic disorder or a history of psychotic disorder must be treated cautiously with a levodopa/dopa-decarboxylase inhibitor because of the risk of exacerbating psychosis.
U bolesnika s velikim psihotičnim poremećajem ili psihotičnim poremećajem u anamnezi, liječenje levodopom / inhibitorom dopa-dekarboksilaze mora se provoditi s oprezom zbog rizika od pogoršanja psihoze.
Cognitive disorder, Horner's syndrome, Dementia
disgeuzija, kognitivni poremećaj, Hornerov sindrom,
Aspartate aminotransferase increased,
Pretrage povišena vrijednost aspartat aminotransferaze,
Caution should be exercised when interpreting the plasma and urine levels of catecholamines and their metabolites in patients on levodopa or levodopa/dopadecarboxylase inhibitor therapy.
Potreban je oprez kada se interpretiraju razine katekolamina i njihovih metabolita u plazmi i urinu bolesnika koji primaju terapiju levodopom ili levodopom / inhibitorom dopa-dekarboksilaze.
63 years
63 godine
Inbrija should be administered with caution in patients with severe cardiovascular disease.
Inbrija se mora primjenjivati s oprezom u bolesnika s teškom kardiovaskularnom bolesti.
Anticholinergic medicinal products may impair the effect of oral levodopa medicinal products, due to a delayed absorption.
Antikolinergični lijekovi mogu umanjiti učinak oralno primijenjenih lijekova koji sadrže levodopu zbog usporavanja apsorpcije.
Abrupt dose reduction or withdrawal of any levodopa medicinal product should be carefully observed, particularly in patients who are also receiving neuroleptics.
Naglo smanjenje doze ili prekid uzimanja lijekova koji sadrže levodopu mora se pažljivo nadzirati, osobito u bolesnika koji primaju i neuroleptike.
Hypromellose Titanium dioxide (E 171) Carrageenan
Ovojnica kapsule hipromeloza titanijev dioksid (E 171)
UPDRS-III score during OFF period n = 95a n = 94a
Rezultat UPDRS-III tijekom OFF-razdoblja n = 95a n = 94a
These inhibitors should already be discontinued for at least two weeks prior to initiating therapy due to the established underlying levodopa therapy (see section 4.5).
Primjena ovih inhibitora morala bi već biti prekinuta najmanje dva tjedna prije započinjanja terapije zbog već uspostavljene postojeće terapije levodopom (vidjeti dio 4.5). - maligni neuroleptički sindrom (MNS) i/ili netraumatska rabdomioliza u dosadašnjoj anamnezi.
The metabolite profile following Inbrija inhalation was not substantially different than that observed following oral carbidopa/levodopa administration.
Profil metabolita nakon inhalacije Inbrije nije bio bitno različit od onog opaženog nakon peroralne primjene karbidope/levodope.
Falsenegative tests may result with the use of glucose-oxidase methods of testing for glucosuria.
Rezultati pretrage na glikozuriju mogu biti lažno negativni ako se koriste metode s glukoza-oksidazom.
Your inhaler is now ready to store.
Inhalator je sada spreman za čuvanje.
Women should not breast-feed during treatment with Inbrija.
Dojilje ne smiju dojiti za vrijeme liječenja Inbrijom.
Get urgent medical help if your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure.
Potražite hitnu medicinsku pomoć ako Vam mišići postanu jako ukočeni ili se snažno trzaju, javi Vam se nevoljno drhtanje, postanete uznemireni, smeteni, dobijete vrućicu, ubrzan puls ili velike oscilacije krvnog tlaka.
The dose-normalised relative bioavailability of a single 66 mg emitted dose of Inbrija was 88.0% (90% CI: 80.3, 96.4) when compared to a single oral carbidopa/levodopa 25 mg/100 mg dose.
Relativna bioraspoloživost normalizirana za dozu je nakon jednokratne, ispuštene doze od 66 mg Inbrije iznosila 88,0% (90% CI: 80,3; 96,4) kada se usporedila s jednokratnom peroralnom dozom karbidope/levodope od 25 mg/100 mg.
Levodopa should be administered cautiously to patients with a history of peptic ulcer disease (because of the possibility of upper gastro-intestinal haemorrhage).
Levodopa se mora primjenjivati s oprezom u bolesnika s peptičkim ulkusom u anamnezi (zbog mogućeg krvarenja u gornjem dijelu gastrointestinalnog trakta).
do not drive or use tools or machines.
Ako se to događa Vama, nemojte upravljati vozilima ili se koristiti alatima i strojevima.
Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
Inbrija je indicirana za intermitentno liječenje epizoda motoričkih fluktuacija (OFF epizoda) u odraslih bolesnika s Parkinsonovom bolešću koji se liječe levodopom / inhibitorom dopa-dekarboksilaze.
Blood lactate dehydrogenase increased,
povišena vrijednost laktat dehidrogenaze u krvi,
A clinical study was performed with Inbrija 66 mg (2 x 33 mg capsules) administered to 56 healthy subjects (31 non-smokers and 25 smokers).
Kliničko ispitivanje primjene Inbrije u dozi od 66 mg (2 kapsule od 33 mg) provedeno je na 56 zdravih ispitanika (31 nepušača i 25 pušača).
Hold the inhaler level and away from your mouth.
Držite inhalator u razini ali odmaknut od usta.
Non-selective Monoamine Oxidase (MAO) inhibitors The use of non-selective MAO inhibitors with levodopa is contraindicated (see section 4.3).
Primjena neselektivnih MAO inhibitora s levodopom je kontraindicirana (vidjeti dio 4.3).
Get inhaler and strip of capsules.
Uzmite inhalator i blister s kapsulama.
There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and a levodopa/dopa-decarboxylase inhibitor.
Rijetko su zabilježene nuspojave, uključujući hipertenziju i diskineziju, kao posljedice istodobne primjene tricikličkih antidepresiva i levodope / inhibitora dopa-dekarboksilaze.
Levodopa is excreted in human milk.
Levodopa se izlučuje u majčino mlijeko.
Common (may affect up to 1 in 10 people): - new or increased abnormal body movements (dyskinesia); - infections of nose, sinuses, throat or lungs; - change in colour of your mucus; - discoloured (i.e. not clear) nasal mucus; - irritation in throat or itchy throat; - feeling sick (nausea); vomiting; - being prone to falls.
Često (može se javiti u najviše 1 na 10 osoba): - novi ili pojačani abnormalni pokreti tijela (diskinezija) - infekcije nosa, sinusa, grla ili pluća - promjene boje sluzi kod iskašljaja - promjena boje (npr. nije bistra) iscjetka iz nosa - nadražaj grla ili svrbež u grlu - mučnina; povraćanje
Pre-dose score Change at 30 min Diff. (95% CI) p-value
Rezultat prije doze Promjena nakon 30 min Razlika (95% CI)
risperidone, chlorpromazine, fluphenazine decanoate, phenotiazine, butyrophenone, or trifluoperazine; - metoclopramide to treat nausea; - isoniazid, an antibiotic to treat tuberculosis; - medicines for high blood pressure, as the dose may need to be adjusted; - medicines for depression called tricyclic antidepressants such as clomipramin, desipramin, or doxepin; - amantadine to treat flu or your Parkinson's disease.
risperidona, klorpromazina, flufenazin dekanoata, fenotiazina, butirofenona ili trifluoperazina - metoklopramid za liječenje mučnine - izoniazid, antibiotik za liječenje tuberkuloze - lijekove za liječenje visokog krvnog tlaka, jer može biti potrebno prilagoditi dozu - lijekove za depresiju koji se nazivaju triciklički antidepresivi poput klomipramina, dezipramina,
The effectiveness of Inbrija for the treatment of OFF episodes in patients with Parkinson's disease given on top of background dopaminergic treatment was evaluated in a 12-week, randomised, placebo-controlled, double-blind study.
Djelotvornost Inbrije u liječenju OFF-epizoda u bolesnika s Parkinsonovom bolešću kada se davala povrh već uspostavljene dopaminergične terapije procijenjena je u randomiziranom, placebom kontroliranom, dvostruko slijepom ispitivanju u trajanju od 12 tjedana.
Abnormal thinking including anxiety, depression, being agitated, being paranoid, delusional, or disorientated, aggressive behaviour and delirious;
Abnormalno razmišljanje koje uključuje tjeskobu, depresiju, uznemirenost, osjećaj paranoje, sumanutosti ili dezorijentiranosti, agresivno ponašanje i delirij
The peak metabolite concentrations and total exposure achieved after Inbrija administration did not exceed those observed following an oral carbidopa/levodopa dose.
Vršna koncentracija metabolita i ukupna izloženost postignuta nakon primjene Inbrije nisu bile veće od onih opaženih nakon peroralne primjene doze karbidope/levodope.
The mean maximal plasma concentration at 10 minutes (C10min) and at peak concentration (Cmax) of levodopa following administration of Inbrija 66 mg (2 x 33 mg capsules) was 418 ng/mL and 696 ng/mL, respectively, with exposure over 4 hours (AUC0-4 h) of 1,280 ng●h/mL.
Srednja vrijednost maksimalne koncentracije u plazmi nakon 10 minuta (C10min) i vršna koncentracija (Cmax) levodope nakon primjene doze Inbrije od 66 mg (2 kapsule od 33 mg) iznosila je 418 ng/ml odnosno 696 ng/ml, s izloženošću tijekom 4 sata (AUC0-4 h) od 1280 ng●h/ml.
and any subsequent updates published on the European medicines web-portal.
Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenima na europskom internetskom portalu za lijekove.
- This medicine is for use by inhalation only.
- Ovo je lijek samo za primjenu inhaliranjem.
A symptom complex resembling neuroleptic malignant syndrome and rhabdomyolysis may occur with levodopa/dopa-decarboxylase inhibitor medicinal products, although no cases have been identified in clinical studies with Inbrija.
Skup simptoma koji nalikuju malignom neuroleptičkom sindromu i rabdomiolizi mogu se javiti kod primjene lijekova koji sadrže levodopu / inhibitor dopadekarboksilaze, ali nije bilo zabilježenih slučajeva u kliničkim ispitivanjima Inbrije.
Package leaflet: Information for the patient Inbrija 33 mg inhalation powder, hard capsules levodopa
Uputa o lijeku: Informacije za bolesnika Inbrija 33 mg prašak inhalata, tvrde kapsule levodopa
The pharmacokinetics of the major levodopa metabolites 3-O-methyldopa (3-OMD), 3,4dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were studied following administration of a single inhaled dose of Inbrija and a single oral carbidopa/levodopa 25 mg/100 mg immediate release tablet.
Farmakokinetika glavnih metabolita levodope 3-O-metildope (3-OMD), 3,4-dihidroksifenilacetatne kiseline (DOPAC) i homovanilinske kiseline (HVA) ispitana je nakon primjene jedne inhalirane doze Inbrije i jedne peroralne doze karbidope/levodope od 25 mg/100 mg u obliku tablete s trenutnim oslobađanjem.
There are no or limited amount of data from the use of levodopa in pregnant women.
Nema podataka ili su podaci o primjeni levodope u trudnica ograničeni.
Carton containing 92 hard capsules (23 blister strips) and one inhaler.
Kutija sadrži 92 tvrde kapsule (23 blistera) i jedan inhalator.
- The used capsule should be removed from the Inbrija inhaler and the second capsule loaded into the inhaler.
- Iskorištenu kapsulu potrebno je ukloniti iz Inbrija inhalatora i u inhalator umetnuti novu kapsulu.
Delusion
deluzija
Because of the risk of bronchospasm, use of levodopa inhalation powder in patients with asthma, chronic obstructive pulmonary disease (COPD), or other chronic underlying lung disease is not recommended.
Zbog rizika za nastanak bronhospazma, ne preporučuje se primjena levodope u obliku praška za inhaliranje u bolesnika s astmom, kroničnom opstruktivnom plućnom bolesti (KOPB) ili drugim podležećim kroničnim plućnim bolestima.
Attach the mouthpiece to the handle by pushing until you hear a click.
Usnik pričvrstite tako da ga pritišćete na držak dok ne začujete škljocaj.
A full dose is 2 capsules.
Puna doza iznosi 2 kapsule.
Talk to your doctor or pharmacist if you develop any of the symptoms below whilst using Inbrija: - sudden sleep attacks or sometimes feeling very sleepy; - changes in or worsening of your mental state, which may be severe such as psychotic and suicidal behaviour; - hallucinations, along with being confused, unable to sleep and excessive dreaming.
Obratite se svom liječniku ili ljekarniku ako se kod Vas, dok uzimate Inbriju, pojave neki od sljedećih simptoma: - iznenadni napadaji spavanja ili se ponekad osjećate jako pospani - promjene ili pogoršanje mentalnog stanja, koje može biti teško poput psihotičnog ili suicidalnog ponašanja
Driving and using machines Inbrija can cause excessive drowsiness, dizziness and sudden sleep attacks.
Inbrija može uzrokovati prekomjernu omamljenost, omaglicu i iznenadne napadaje spavanja.
A clinical study was performed with Inbrija 66 mg (2 x 33 mg capsules) in 24 healthy subjects (13 men and 11 women).
Kliničko ispitivanje primjene Inbrije u dozi od 66 mg (2 kapsule od 33 mg) provedeno je na 24 zdrava ispitanika (13 muškaraca i 11 žena).
Carton containing 60 hard capsules (15 blister strips) and one inhaler.
Kutija sadrži 60 tvrdih kapsula (15 blistera) i jedan inhalator.
• You should inhale the contents of the second capsule within 10 minutes of the first one.
• Sadržaj druge kapsule morate udahnuti unutar 10 minuta nakon prve kapsule.
Contains colfosceril palmitate (DPPC), sodium chloride, hypromellose, titanium dioxide (E 171), carrageenan, potassium chloride, carnauba wax, maize starch, shellac, black iron oxide (E 172), propylene glycol, potassium hydroxide.
Sadrži kolfoscerilpalmitat (DPPC), natrijev klorid, hipromelozu, titanijev dioksid (E 171), karagenan, kalijev klorid, karnauba vosak, kukuruzni škrob, šelak, crni željezov oksid (E 172), propilenglikol,
Adverse reactions reported with oral levodopa
Nuspojave prijavljene s peroralnom levodopom
Blood and lymphatic system disorders
Poremećaji krvi i limfnog sustava anemija,
Psychotic disorder, Impulse-control disorder (see section 4.4),
psihotični poremećaji, poremećaj kontrole nagona (vidjeti dio 4.4),
Use one capsule at a time.
Kapsule primijenite jednu po jednu.
- The medicine must be used only with the Inbrija inhaler device.
- Ovaj lijek se smije primijeniti samo pomoću Inbrija inhalatora.
You should inhale the contents of the second capsule within 10 minutes of the first one.
Sadržaj druge kapsule morate udahnuti unutar 10 minuta nakon prve kapsule.
Breast-feeding should be discontinued during treatment with Inbrija.
Dojenje treba prekinuti za vrijeme liječenja lijekom Inbrija.
- The other ingredients comprising the powder and capsule are colfosceril palmitate (DPPC), sodium chloride, hypromellose, titanium dioxide (E 171), carrageenan, potassium chloride, carnauba wax, maize starch, shellac, black iron oxide (E 172), propylene glycol and potassium hydroxide.
- Drugi sastojci praška i kapsule su kolfoscerilpalmitat (DPPC) natrijev klorid, hipromeloza, titanijev dioksid (E 171), karagenan, kalijev klorid, karnauba vosak, kukuruzni škrob, šelak, crni željezov oksid (E 172), propilenglikol i kalijev hidroksid.
Thrombophlebitis, Hot flush
tromboflebitis, navale vrućine
A summary of how to use Inbrija is provided below.
Sažetak kako primjenjivati Inbriju nalazi se u nastavku.
- a carton containing 60 hard capsules (15 blister strips) and one inhaler - a carton containing 92 hard capsules (23 blister strips) and one inhaler
Veličine pakiranja su - kutija sa 60 tvrdih kapsula (15 blistera) i jedan inhalator - kutija sa 92 tvrde kapsule (23 blistera) i jedan inhalator
You should hear the capsule “whirl”.
Trebate čuti da se kapsula „zavrtjela“.
Vision blurred, Diplopia, Mydriasis, Oculogyric crisis, Blepharospasm
midrijaza, okulogirična kriza, blefarospazam
Bacterial test positive, Weight decreased,
pozitivni test na prisutnost bakterija,
Dispose and store Step 12: Dispose of used capsules
Odlaganje i čuvanje 12. korak: Odlaganje iskorištenih kapsula Iskorištene kapsule zbrinite u skladu s nacionalnim propisima.
Selective Monoamine Oxidase (MAO) inhibitors
Selektivni inhibitori monoaminooksidaze (MAO)
- blurred vision; double vision; widening pupil; prolonged rolling eyes upwards; involuntary tight closure of the eyelids; - heart problems, a noticeably rapid, strong, or irregular heartbeat; - low blood pressure soon after standing up; high blood pressure; fainting; blood clot in a vein; hot flushes; - shortness of breath; difficulty in breathing; difficulty in speaking; hiccups; - stomach pains; constipation; diarrhoea; dry mouth; stomach and intestinal bleeding; stomach ulcer; difficulty in swallowing; indigestion; burning sensation in the mouth; passing wind; change in colour of saliva; more saliva than normal; - swelling of face, lips, tongue, limbs and genitals; excessive sweating; rash; severe itching of the skin; condition called Henoch-Schoenlein purpura, the symptoms of which include a purple spotted skin rash; allergic reaction causing a rash of round, red welts on the skin that itch intensely; hair loss; discoloured sweat; - muscle spasms; lockjaw; - difficulty in emptying the bladder; abnormal urine colour; loss of bladder control; - painful, abnormally long-lasting erection; - swelling of lower legs or hands; feeling weak and having no energy; feeling tired; lack of energy; difficulty in walking; chest pain; - abnormal blood investigation results; weight loss; weight gain.
- poremećaji pokreta pri čemu se mišići osobe nekontrolirano kontrahiraju; iznenadne, ponekad nepredvidive promjene simptoma zbog povratka simptoma Parkinsonove bolesti; pospanost; omaglica; pogoršanje Parkinsonove bolesti; osjećaj trnaca i bockanja; glavobolja, nevoljno drhtanje; napadaji; iznenadno padanje u san; sindrom nemirnih nogu; ataksija (poremećaj koji utječe na koordinaciju pokreta, ravnotežu i govor); poremećen osjet okusa; poremećaji mentalnog stanja koji zahvaćaju sposobnost učenja, pamćenja, opažanja i rješavanja problema; Hornerov sindrom (poremećaj oka); demencija - zamućen vid; dvoslike; proširenje zjenica; dugotrajno okretanje očiju prema gore; nevoljno čvrsto stiskanje vjeđa - srčani problemi, osjetno brzi, snažni ili nepravilni otkucaji srca - niski krvni tlak odmah nakon ustajanja u uspravni položaj; visoki krvi tlak; nesvjestica; krvni ugrušak u veni; navale vrućine - nedostatak zraka; otežano disanje; otežani govor; štucanje - bol u želucu; zatvor; proljev; suha usta; krvarenje iz želuca ili crijeva; čir na želucu; otežano gutanje; probavne tegobe; osjećaj pečenja u ustima; vjetrovi; promjena boje sline; obilnije stvaranje sline nego je to normalno
The pharmacokinetics of Inbrija 66 mg (2 x 33 mg capsules) and carbidopa/levodopa 25 mg/100 mg immediate release tablets was evaluated in 24 healthy volunteers in a fasted state receiving a total of 50 mg carbidopa every 8 hours.
Farmakokinetika Inbrije u dozi od 66 mg (2 kapsule od 33 mg) i karbidope/levodope u dozi od 25 mg/100 mg u obliku tablete s trenutnim oslobađanjem procijenjena je u 24 zdrava dobrovoljca koji su u stanju natašte primali ukupno 50 mg karbidope svakih 8 sati.
Step 10: Remove capsule from inhaler Twist and pull off the mouthpiece
10. korak: Izvadite kapsulu iz inhalatora Zakrenite, povucite i odvojite usnik
Patients should be on a stable levodopa/dopa-decarboxylase inhibitor (e.g. carbidopa or benserazide) regimen before starting Inbrija.
Prije početka primjene Inbrije bolesnici moraju biti na stabilnom režimu doziranja levodope / inhibitora dopa-dekarboksilaze (npr. karbidope ili benserazida).
Withdrawal-emergent hyperpyrexia and confusion
Hiperpireksija i konfuzija nakon prekida terapije
- medicines for your Parkinson's disease called selective MAO inhibitors such as rasagiline, selegiline and safinamide, COMT inhibitors such as entacapone, tolcapone and opicapone, or anticholinergics such as orphenadrine and trihexyphenidyl;
Obavijestite svog liječnika ili ljekarnika ako uzimate: - lijekove za liječenje Parkinsonove bolesti koji se nazivaju selektivni MAO inhibitori, poput razagilina, selegilina i safinamida, inhibitore KOMT-a poput entakapona, tolkapona i opikapona, ili antikolinergike poput orfenadrina i triheksifenidila - lijekove za liječenje psihičkih stanja uključujući shizofreniju poput benperidola, haloperidola,
COMT inhibitors
Inhibitori KOMT-a
There is limited data regarding chronic effect of Inbrija in respiratory compromised patients.
Podaci o kroničnim učincima Inbrije na bolesnike s kompromitiranom respiracijom su ograničeni.
- A complete dose is 2 capsules taken one right after the other.
- Puna doza iznosi 2 kapsule primijenjene jedna iza druge.
• Make sure your hands are clean and dry when using the inhaler and capsules.
• Kada koristite inhalator i kapsule, pazite da Vam ruke budu čiste i suhe.
The change from baseline for DLCO was compared between the Inbrija treatment group and the observational cohort; at the end of 12 months, there was no significant difference in the change from baseline between Inbrija group and the observational cohort in DLCO.
Promjene u odnosu na početne vrijednosti za DLCO uspoređene su između skupine liječene Inbrijom i opservacijske skupine na kraju razdoblja od 12 mjeseci; nije bilo značajne razlike u promjeni DLCO u odnosu na početne vrijednosti između skupine koja je primala
Worsening of Parkinson's disease,
Trajanje Parkinsonove bolesti
It is recommended to administer this medicinal product cautiously to patients with severe hepatic impairment (see section 4.2).
Preporučuje se lijek primjenjivati s oprezom u bolesnika s teškom bolešću bubrega (vidjeti dio 4.2).
Palpitations
palpitacije
Inbrija is a medicine used by inhalation for treating the worsening of your symptoms during the “off periods” of Parkinson's disease.
Inbrija je lijek koji se primjenjuje inhaliranjem za liječenje pogoršanja simptoma tijekom tzv. „off razdoblja“ kod Parkinsonove bolesti (razdoblja zakočenosti i nepokretnosti).
Care should be exercised when Inbrija is administered to patients with a history of myocardial infarction who have residual atrial, nodal, or ventricular arrhythmias.
Potreban je oprez kada se Inbrija primjenjuje u bolesnika koji u anamnezi imaju infarkt miokarda s posljedičnim atrijalnim, nodalnim ili ventrikularnim aritmijama.
- Two capsules of medicine should be inhaled to get the full dose.
- Da bi se uzela puna doza lijeka, moraju se inhalirati dvije kapsule lijeka.
Cases of falsely diagnosed pheochromocytoma in patients on levodopa/dopa-decarboxylase inhibitor therapy have been reported very rarely.
Slučajevi krive dijagnoze feokromocitoma u bolesnika koji primaju terapiju levodopom / inhibitorom dopa-dekarboksilaze zabilježeni su vrlo rijetko.
You may need to have tests on your heart, liver, kidney, and blood cell tests during long-term treatment with your medicines.
Tijekom dugotrajnog uzimanja lijekova možda ćete trebati učiniti pretrage srca, jetre, bubrega i krvne slike.
Reduction in mean daily OFF time and improvement on the Patient Global Impression of Change (PGI-C) scale, a patient reported outcome of the overall improvement and satisfaction with Inbrija treatment, and Responders ON were the main secondary endpoints.
Patient Global Impression of Change scale, PGI-C scale), sveukupno poboljšanje i zadovoljstvo liječenjem Inbrijom prema navodu samog bolesnika i bolesnici s ON odgovorom.
How to use Inbrija
Kako uzimati Inbriju
Interference with test
Interferencija s laboratorijskim pretragama
Do not swallow capsules.
Ne gutati kapsule.